Pricing Log in Create free account
Friday 6 November 2026 Export CORT’s income statement to Excel — free account

Corcept Therapeutics Incorporated

CORT Healthcare Biotechnology

Corcept Therapeutics Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $761.4 million, up 12.8% from fiscal 2024.

Revenue
+64.0%
EPS
+525.8%
Free cash flow
+161.0%

Quarter to September 2026, against a year earlier

72.63 1.00 +1.40%
Market cap
$7.8B
P/E
47.8×
Fwd P/E
39.8×
Dividend yield
—
F-score
4/9
Altman Z
14.11
Beneish M
−2.76
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Valuation Filings

Corcept Therapeutics Incorporated (CORT) EV/Sales

Alert me on EV/Sales

As of 6 November 2026, Corcept Therapeutics Incorporated (CORT) trades at a EV/Sales of 7.7×. Over the past ten years it has ranged from 2.9× (April 2020) to 22.6× (March 2015); the current reading is higher than 57% of that period. That is below the Biotechnology industry median of 9.0× and above the Healthcare sector median of 3.5×.

EV/Sales, daily

Embed this chart

Annual newest first

Period EV/Sales Change
FY2025 4.3× (40.27%)
FY2024 7.2× 61.11%
FY2023 4.4× 3.09%
FY2022 4.3× (24.02%)
FY2021 5.7× (22.43%)
FY2020 7.3× 100.27%
FY2019 3.7× (31.91%)
FY2018 5.4× (56.96%)
FY2017 12.5× 29.85%
FY2016 9.6× (6.79%)

Quarterly newest first

Period EV/Sales Change
Sep 2026 12.4× 15.98%
Jun 2026 10.7× 111.25%
Mar 2026 5.1× 18.13%
Dec 2025 4.3× (61.33%)
43 more quarters

Against its own ten years

Low 2.9× High 22.6×
Ten-year median 6.8×
Current reading's percentile 62

EV/Sales against peers

Company EV/Sales
ABVX Abivax SA Sponsored ADR compare n/m
CORT Corcept Therapeutics Incorporated 7.6×
MDGL Madrigal Pharmaceuticals, Inc. compare 7.8×
ARWR Arrowhead Pharmaceuticals, Inc. compare 11.2×
KRYS Krystal Biotech, Inc. compare 17.0×
PTGX Protagonist Therapeutics, Inc. compare 28.9×
CYTK Cytokinetics, Incorporated compare 65.9×
PRAX Praxis Precision Medicines, Inc. compare 812×
SYRE Spyre Therapeutics, Inc. compare 7,143×
Biotechnology industry median 9.0×
Healthcare sector median 3.5×
Market median 2.1×

What EV/Sales is

EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)

The full definition of EV/Sales →

More on CORT